Once a Month, Not Once a Day: How Long-Acting Injectable HIV Therapies Are Transforming Treatment on Every Level

For more than two decades, the architecture of HIV treatment has rested on a familiar foundation: a daily pill, taken at roughly the same time each day, every day, indefinitely. That regimen has saved countless lives and driven viral suppression to levels once considered impossible. But it has also imposed a quiet, persistent burden — a daily reminder of a diagnosis, a logistical challenge for travelers, a source of anxiety for anyone who fears accidental disclosure.

A new class of long-acting therapies is beginning to dismantle that structure entirely. Injectable antiretroviral treatments administered once monthly or even less frequently are now FDA-approved and in use across the United States, representing one of the most meaningful shifts in HIV care since combination therapy emerged in the 1990s. For patients and clinicians alike, the implications extend well beyond convenience.

What Long-Acting HIV Treatment Actually Means

The term "long-acting" refers to antiretroviral formulations engineered to remain active in the body for weeks or months after a single administration, rather than requiring daily oral dosing. The first FDA-approved regimen in this category — cabotegravir plus rilpivirine, marketed under the brand name Cabenuva — consists of two injectable medications given together once monthly or, under an updated dosing schedule, once every two months.

Cabotegravir is an integrase strand transfer inhibitor, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they constitute a complete two-drug antiretroviral regimen delivered by intramuscular injection, typically administered by a healthcare provider in a clinical setting. The transition to this regimen generally requires a brief oral lead-in period to assess tolerability before the first injections are given.

Separately, a long-acting injectable formulation of cabotegravir alone — Apretude — has also received FDA approval for use as pre-exposure prophylaxis (PrEP), administered every two months. While this article focuses primarily on treatment rather than prevention, the existence of both applications underscores the breadth of this therapeutic shift.

The Clinical Evidence Behind the Transition

The ATLAS and FLAIR clinical trials, which supported the original approval of cabotegravir plus rilpivirine, demonstrated that the injectable regimen was non-inferior to daily oral antiretroviral therapy in maintaining viral suppression among adults who were already virologically stable. In other words, patients who switched from a daily pill regimen to monthly injections were just as likely to maintain an undetectable viral load.

Subsequent data from the ATLAS-2M trial extended this finding to the every-two-month dosing interval, showing that bimonthly injections were non-inferior to monthly injections — a finding that further expanded the practical appeal of this approach. Across these studies, the proportion of participants maintaining HIV RNA below 50 copies per milliliter remained high and consistent.

Importantly, these trials also captured patient-reported outcomes. Participants receiving the injectable regimen consistently reported high satisfaction scores, with many citing reduced treatment burden and improved quality of life as primary drivers. The psychological dimension of no longer needing to take — or remember to take — a daily pill carried measurable weight in how participants described their experience of living with HIV.

Who Is a Candidate — and Who May Not Be

Long-acting injectable therapy is not universally appropriate. Current FDA labeling specifies that cabotegravir plus rilpivirine is indicated for adults who are virologically stable on their current regimen, defined as an HIV RNA below 50 copies per milliliter, with no history of treatment failure and no known resistance to either cabotegravir or rilpivirine.

Certain resistance-associated mutations — particularly those affecting the rilpivirine component — can preclude use of this regimen. Resistance testing prior to initiation is therefore a standard component of the evaluation process. Patients with a history of virologic failure on regimens containing non-nucleoside reverse transcriptase inhibitors may require additional assessment before being considered candidates.

Body weight can also be a clinical consideration. Some data have suggested that individuals with higher body mass index may experience altered drug pharmacokinetics with rilpivirine, though this remains an area of ongoing study. Clinicians are encouraged to conduct individualized assessments rather than applying blanket restrictions.

Practical logistics matter as well. The current labeling requires that injections be administered by a healthcare provider, meaning patients must have reliable access to a clinic or physician's office on a monthly or bimonthly basis. For individuals in rural areas, those without consistent transportation, or those with inflexible work schedules, this requirement may present its own adherence challenge — a different kind than missing a daily pill, but a challenge nonetheless.

What the Transition Looks Like in Practice

For patients who are candidates, the process of switching to long-acting injectable therapy typically begins with a conversation — often initiated by the patient — about treatment goals, lifestyle factors, and any concerns about the injection process itself. Many patients report initial hesitation about needles, which clinicians can address through education about injection site management and what to expect in terms of local reactions.

Injection site reactions — including pain, nodules, and swelling at the gluteal injection site — are among the most commonly reported side effects and tend to be most pronounced after the first few injections. For the majority of patients in clinical trials, these reactions were mild to moderate in severity and diminished over time. Systemic side effects were generally comparable to or less frequent than those associated with oral regimens.

Patients who have made the transition frequently describe a recalibration of how HIV fits into their daily identity. The daily pill, for many, functions as a constant low-level reminder of their diagnosis. Removing it from the routine can carry unexpected emotional weight — a sense of reclaiming normalcy that is difficult to quantify in clinical endpoints but deeply meaningful in lived experience.

The Broader Landscape: What Comes Next

The approval of cabotegravir plus rilpivirine represents a beginning rather than an endpoint in the evolution of long-acting HIV therapy. Lenacapavir, a capsid inhibitor with an exceptionally long half-life, has received FDA approval for use in heavily treatment-experienced adults with multidrug-resistant HIV and is administered subcutaneously every six months. Its potential role in treatment-naive populations is under active investigation.

Researchers are also exploring implantable drug delivery systems, broadly neutralizing antibodies, and other platforms designed to extend dosing intervals even further — potentially to annual or semi-annual administration. While most of these approaches remain in clinical development, the trajectory is clear: the field is moving decisively away from daily oral dosing as the default standard of care.

A Conversation Worth Having

For people living with HIV who are currently stable on oral therapy, the emergence of long-acting injectables does not demand an immediate decision. Daily oral antiretroviral therapy remains highly effective, well-tolerated, and appropriate for the vast majority of patients. The goal is not to replace one regimen with another universally, but to expand the menu of viable options so that treatment can be genuinely individualized.

What long-acting therapy does demand is an informed conversation with your HIV care provider. Questions about eligibility, logistics, side effect expectations, and personal treatment goals are all relevant. Understanding what the clinical evidence actually shows — as opposed to what it is sometimes assumed to show — is the foundation of that conversation.

At Roche HIV Resource Center, our commitment is to ensure that people living with HIV have access to the clearest, most current information available. The evolution of long-acting therapies is one of the most significant developments in HIV care in a generation. Knowing what it means — and whether it might be right for you — is a form of empowerment in itself.